By Michael Dabaie

Abbott Laboratories said the U.S. Food and Drug Administration cleared its next-generation FreeStyle Libre 3 system for use by people four years and older with diabetes.

The company said the FreeStyle Libre 3 system will be available at the same price as previous versions and is the most accurate 14-day continuous glucose monitor, with readings sent directly to a smartphone every minute.

The FreeStyle Libre 3 system was cleared for use with the FreeStyle Libre 3 iOS and Android mobile apps. The FreeStyle Libre 3 sensor will be available at participating pharmacies later this year.

Abbott in late April said results from a new meta-analysis of 75 real-world, observational studies demonstrated that its FreeStyle Libre system provides significant reductions in glycated hemoglobin that are sustained up to 24 months in adults with both type 1 and type 2 diabetes.

Write to Michael Dabaie at michael.dabaie@wsj.com

(END) Dow Jones Newswires

May 31, 2022 09:00 ET (13:00 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Abbott Laboratories (NYSE:ABT)
Historical Stock Chart
Von Mär 2024 bis Apr 2024 Click Here for more Abbott Laboratories Charts.
Abbott Laboratories (NYSE:ABT)
Historical Stock Chart
Von Apr 2023 bis Apr 2024 Click Here for more Abbott Laboratories Charts.